Form 4: RxSight Executive Sells Shares Under 10b5-1 Plan After Option Exercises

An RxSight executive, Ilya Goldshleger, executed stock option exercises and subsequent sales under a pre-arranged 10b5-1 trading plan.

Summary

• Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc., exercised stock options to acquire 7,975 shares of common stock at a price of $15.08 per share.
• Following the option exercises, Mr. Goldshleger sold 7,975 shares of common stock at prices ranging from $45 to $46 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 3, 2024.
• After these transactions, Mr. Goldshleger directly owns 42,246 shares of common stock and indirectly owns 1,372 shares through his spouse.
• He also holds options to purchase 50,082 shares of common stock.

Sentiment

Score: 6

Explanation: The document reflects routine executive transactions under a pre-arranged plan, which is neither overly positive nor negative. The sales are expected and do not indicate any significant change in the company's outlook.

Positives

• The executive's pre-planned sales under a 10b5-1 plan suggest an orderly and transparent approach to stock transactions.
• The exercise of options at $15.08 and subsequent sales at $45-$46 indicates a significant profit for the executive.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is part of a pre-arranged plan.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes create short-term price volatility.
• There is a risk that further sales by the executive could put downward pressure on the stock price.

Future Outlook

The executive's future transactions will likely continue to be governed by the existing 10b5-1 trading plan.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2024 by the Reporting Person.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies like RxSight, similar to practices at companies such as Alcon or Johnson & Johnson, which also have executives who regularly exercise options and sell shares.
• The vesting schedule of the options, with 1/48th vesting monthly, is a typical vesting schedule for equity grants in the technology and medical device industries, similar to companies like Intuitive Surgical or Medtronic.

Stakeholder Impact

• Shareholders may be interested in the executive's transactions, but the pre-planned nature of the sales should mitigate any negative impact.
• Employees may view the executive's stock sales as a normal part of compensation.

Key Dates

Keywords

RxSight, insider trading, Form 4, stock options, Rule 10b5-1, executive compensation, Ilya Goldshleger, stock sale